EUDA Price To Sales Ratio from 2010 to 2024
EUDA Stock | 4.32 0.07 1.59% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 10.51207439 | Current Value 11.84 | Quarterly Volatility 6.59776668 |
Check EUDA Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among EUDA Health's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 183.4 K or Interest Expense of 22.1 K, as well as many indicators such as Price To Sales Ratio of 11.84, Dividend Yield of 0.0 or Days Sales Outstanding of 22.38. EUDA financial statements analysis is a perfect complement when working with EUDA Health Valuation or Volatility modules.
EUDA | Price To Sales Ratio |
Latest EUDA Health's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of EUDA Health Holdings over the last few years. Price to Sales Ratio is figured by comparing EUDA Health Holdings stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on EUDA Health sales, a figure that is much harder to manipulate than other EUDA Health Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. EUDA Health's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in EUDA Health's overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 42.11 X | 10 Years Trend |
|
Price To Sales Ratio |
Timeline |
EUDA Price To Sales Ratio Regression Statistics
Arithmetic Mean | 18.29 | |
Geometric Mean | 16.06 | |
Coefficient Of Variation | 36.06 | |
Mean Deviation | 5.37 | |
Median | 21.95 | |
Standard Deviation | 6.60 | |
Sample Variance | 43.53 | |
Range | 19.9398 | |
R-Value | (0.71) | |
Mean Square Error | 23.34 | |
R-Squared | 0.50 | |
Significance | 0 | |
Slope | (1.05) | |
Total Sum of Squares | 609.43 |
EUDA Price To Sales Ratio History
About EUDA Health Financial Statements
EUDA Health stakeholders use historical fundamental indicators, such as EUDA Health's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although EUDA Health investors may analyze each financial statement separately, they are all interrelated. For example, changes in EUDA Health's assets and liabilities are reflected in the revenues and expenses on EUDA Health's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in EUDA Health Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 10.51 | 11.84 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether EUDA Health Holdings is a strong investment it is important to analyze EUDA Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact EUDA Health's future performance. For an informed investment choice regarding EUDA Stock, refer to the following important reports:Check out the analysis of EUDA Health Correlation against competitors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EUDA Health. If investors know EUDA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EUDA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.144 | Quarterly Revenue Growth (0.14) | Return On Assets (0.86) |
The market value of EUDA Health Holdings is measured differently than its book value, which is the value of EUDA that is recorded on the company's balance sheet. Investors also form their own opinion of EUDA Health's value that differs from its market value or its book value, called intrinsic value, which is EUDA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EUDA Health's market value can be influenced by many factors that don't directly affect EUDA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EUDA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if EUDA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EUDA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.